BONESUPPORT HOLDING AB AI Stock Analysis
Want to see SE:BONEX full AI Analyst Report?
BONESUPPORT HOLDING AB (BONEX) AI Stock Analysis
BONESUPPORT HOLDING AB
(Nasdaq OMX AB:BONEX)
Excellent financial performance with a pristine balance sheet and robust cash flows, combined with positive earnings call highlights including strong growth and guidance, form the foundation of the score. Technical momentum supports but high valuation caps the overall rating.
BONESUPPORT HOLDING AB (BONEX) vs. iShares MSCI Sweden ETF (EWD)
- Market Cap
- SEK 2.08B
- Dividend Yield
- ―
- Average Volume (3M)
- 370.65K
- Price to Earnings (P/E)
- 75.9
- Beta (1Y)
- 0.44
- Revenue Growth
- 25.20%
- EPS Growth
- 79.34%
- Country
- Sweden
- Employees
- 171
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
BONESUPPORT HOLDING AB Business Overview & Revenue Model
Company Description
Bonesupport Holding AB (publ) is an orthobiologics company that specializes in the development and commercialization of injectable bioceramic bone graft substitutes. These products are utilized for treating bone voids and are available internationall...
How the Company Makes Money
BONESUPPORT primarily makes money by selling its CERAMENT-branded bone graft substitute products to hospitals and healthcare providers, generating revenue from procedure-driven usage in orthopedic, trauma, and infection-related bone reconstruction ca...
BONESUPPORT HOLDING AB Earnings Call Summary
The call was strongly positive, driven by 38% constant-currency sales growth, improved operating margins, strong cash generation, continued U.S. CERAMENT G adoption, favorable CMS reimbursement changes, and positive SOLARIO results. The company also reaffirmed full-year growth guidance and reported progress on CERAMENT V and its spine strategy. Offsetting factors included higher commercial costs, a decline in U.S. gross margin, flat CERAMENT BVF sales, continued go-stop-go adoption patterns, and pending regulatory and clinical milestones.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
BONESUPPORT confirmed its previously communicated full-year outlook of sales growth between 33% and 36% in constant currency, based on continued commercial execution on existing baselines and “normalized commercial execution”; management does not expect CMS to have a material impact on revenue in Q4, but expects the ruling to help adoption and access over time and be an important topic in the coming quarters, with positive impact in the quarters to come. Management expects go-stop-go dynamics to continue in Q4 as well as next year, expects U.S. growth of 30%, 40% to require continued investment in the commercial organization, including accelerating administrator-focused hiring in the coming quarter as well as in the next year, and said it expects a formal FDA reply on CERAMENT V sometime in Q4 or Q1, followed by a couple of months between approval and starting sales.
BONESUPPORT HOLDING AB Financial Statement Overview
Summary
Robust revenue growth, high gross margins, exceptional balance sheet with minimal debt, and strong free cash flow generation.
Income Statement
84Very PositiveBalance Sheet
96Very PositiveCash Flow
91Very Positive| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.40B | 1.17B | 898.73M | 591.08M | 328.82M | 212.88M |
| Gross Profit | 1.29B | 1.09B | 832.25M | 540.92M | 300.78M | 190.03M |
| EBITDA | 366.50M | 288.25M | 185.75M | 28.94M | -54.34M | -72.39M |
| Net Income | 271.77M | 142.15M | 133.75M | 245.02M | -68.17M | -85.53M |
Balance Sheet | ||||||
| Total Assets | 1.17B | 1.04B | 879.69M | 688.82M | 371.82M | 343.92M |
| Cash, Cash Equivalents and Short-Term Investments | 510.52M | 377.99M | 227.00M | 167.35M | 201.28M | 206.46M |
| Total Debt | 10.63M | 11.68M | 14.59M | 17.48M | 17.45M | 21.42M |
| Total Liabilities | 176.35M | 168.88M | 152.23M | 143.64M | 102.89M | 78.22M |
| Stockholders Equity | 992.49M | 867.26M | 727.46M | 545.18M | 268.93M | 265.70M |
Cash Flow | ||||||
| Free Cash Flow | 329.35M | 216.11M | 59.92M | -24.32M | -48.94M | -86.84M |
| Operating Cash Flow | 333.55M | 221.30M | 65.76M | -18.26M | -46.98M | -83.42M |
| Investing Cash Flow | -5.43M | -5.88M | -6.26M | -6.06M | -3.28M | -3.42M |
| Financing Cash Flow | -199.51M | -58.04M | -4.81M | -6.70M | 42.78M | -61.56M |
BONESUPPORT HOLDING AB Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:BONEX, the sentiment is Positive. The current price of 313.60 is below the 20-day moving average (MA) of 317.72, above the 50-day MA of 264.52, and above the 200-day MA of 228.00, indicating a neutral trend. The MACD of 15.33 indicates Positive momentum. The RSI at 57.93 is Neutral, neither overbought nor oversold. The STOCH value of 49.90 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:BONEX.
BONESUPPORT HOLDING AB Peers Comparison
Overall Rating
SE:BONEX78Outperform
SE:GETI.B67Neutral
SE:BACTI.B53Neutral
SE:OSSD52Neutral
SE:INTEG.B49Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 78Outperform | SEK 20.65B | 75.93 | 29.00% | ― | 25.20% | 79.34% | |
| 67Neutral | SEK 75.53B | 26.69 | 9.13% | 1.71% | -3.90% | 37.73% | |
| 53Neutral | SEK 544.93M | 86.39 | 1.93% | ― | -0.51% | ― | |
| 52Neutral | SEK 368.38M | -7.36 | ― | ― | -11.89% | -11.85% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 49Neutral | SEK 242.60M | -5.75 | -20.71% | ― | 1.43% | 4.98% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| SE:BONEX | BONESUPPORT HOLDING AB | 313.60 | 116.40 | 59.03% | |
| SE:GETI.B | Getinge AB (UK) | 277.30 | 74.58 | 36.79% | |
| SE:BACTI.B | Bactiguard Holding AB | 15.55 | -3.20 | -17.07% | |
| SE:INTEG.B | Integrum AB Class B | 8.27 | -0.44 | -5.05% | |
| SE:PRO | Promimic AB | 8.35 | -8.40 | -50.15% | |
| SE:OSSD | OssDsign AB | 3.33 | -7.41 | -68.99% |
BONESUPPORT HOLDING AB Corporate Events
BONESUPPORT Posts Strong Q3 Growth as Reimbursement and Clinical Data Bolster Strategy
BONESUPPORT delivered a strong third quarter, with net sales climbing 39 percent to SEK 408.8 million and adjusted operating profit rising to SEK 139.3 million, supported by robust growth in both its US and Europe & Rest of World segments and gross m...
BONESUPPORT schedules Q3 2026 report and investor webcast
BONESUPPORT Holding AB will publish its interim report for the third quarter of 2026 on October 22 at 08:00 CEST, underscoring ongoing investor interest in the orthobiologics specialist’s financial performance. The company will follow the release wit...
BONESUPPORT Advances SEK 100m Share Buy-Back to Adjust Capital Structure
BONESUPPORT Holding AB has continued executing its share buy-back program during the week of October 5–9, 2026, repurchasing a total of 60,000 ordinary shares on Nasdaq Stockholm for approximately SEK 13.8 million. The transactions were carried out b...
BONESUPPORT Expands Share Buy-Back as Treasury Holdings Grow
BONESUPPORT HOLDING AB has continued its ongoing share buy-back programme, repurchasing 60,000 ordinary shares on Nasdaq Stockholm between 21 and 25 September 2026 for a total of about SEK 12.8 million at an average price of SEK 213.59. These purchas...
BONESUPPORT Builds Momentum for CERAMENT as U.S. Reimbursement and Clinical Data Align
BONESUPPORT is leveraging its CERAMENT technology platform to address orthopedic infections and bone injuries with injectable, resorbable bone graft substitutes that can deliver local antibiotic therapy. The company’s focus on demonstrating clinical...
BONESUPPORT Expands Share Buy-Back to Strengthen Capital Structure
BONESUPPORT Holding AB has continued its share buy-back program, repurchasing 68,000 ordinary shares on Nasdaq Stockholm between September 14 and 18, 2026 for a total of about SEK 14.9 million. The program, capped at SEK 100 million and running until...
BONESUPPORT Submits Full Data Package for CERAMENT V De Novo to FDA
BONESUPPORT has submitted the complete additional data package for its CERAMENT V De Novo application to the U.S. Food and Drug Administration, marking a key regulatory step for its drug-eluting bone graft substitute. The move could strengthen the co...
BONESUPPORT’s SOLARIO Study in NEJM Backs Shorter Antibiotic Courses for Bone Infections
BONESUPPORT announced that the SOLARIO study, a major multi‑centre randomized trial in orthopedic infections, has been published in The New England Journal of Medicine. The study evaluated whether systemic antibiotic courses could be safely reduced t...
BONESUPPORT Taps Stryker for Australia and New Zealand Expansion
BONESUPPORT has entered a new distributor partnership with Stryker Australia Pty Ltd, marking its expansion into the New Zealand market and a shift to Stryker as distributor in Australia. The transition, planned for the fourth quarter of 2026, streng...
BONESUPPORT Launches SEK 100m Share Buy-Back to Optimize Capital Structure
BONESUPPORT Holding AB has initiated a share buy-back programme of up to SEK 100 million to adjust its capital structure to better match capital needs and support shareholder value. The programme, conducted under EU Market Abuse and Safe Harbour regu...
BONESUPPORT Launches SEK 100 Million Share Buy-Back to Adjust Capital Structure
BONESUPPORT’s board has authorized a share buy-back program of up to SEK 100 million, aiming to optimize the company’s capital structure and enhance shareholder value. The program will run between September 1 and October 30, 2026, with purchases cond...
BONESUPPORT Faces FDA Timeline Extension for CERAMENT V De Novo Submission
BONESUPPORT has announced that the U.S. Food and Drug Administration has extended the deadline for the additional data package in the De Novo submission for its antibiotic-eluting bone graft product CERAMENT V. The revised timeline stems from a speci...
CMS Grants Higher U.S. Reimbursement for BONESUPPORT’s CERAMENT G
BONESUPPORT has secured a favorable decision from the U.S. Centers for Medicare & Medicaid Services, which confirmed a DRG reassignment that will place CERAMENT G cases in the highest reimbursing diagnosis-related groups within their clinical categor...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 23, 2026
